Emerging pathways can help cell and gene therapies become commercially viable for intractable diseases, even with uneven scalability and consistency.

Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...

General Motors Co. and its supplier Piston Automotive are planning a hydrogen fuel cell manufacturing plant at the old State Fairgrounds site in Detroit. The project, in its beginning stages, would be ...

India’s solar industry faces supply challenges as domestic cell capacity lags module growth under evolving ALMM sourcing ...